13 completed, 4 terminated, 1 withdrawn. 9 Phase 2, 7 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Terminated 2, Withdrawn 1 |
| Phase 3 | 7 | Completed 5, Terminated 2 |
| Phase 1 | 2 | Completed 2 |
Follow fevipiprant: new trials by email Literature Review of fevipiprant trials Research Report on fevipiprant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma. QAW039 - Asthma, Asthma, Bronchial | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2019-10-15 | 2020-05-14 | |
| A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia QAW039, Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Terminated | Novartis Pharmaceuticals | 9 | 2019-05-21 | 2021-10-08 |
| Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With Asthma Fevipiprant - Asthma | Phase 2 | Terminated | Novartis Pharmaceuticals | 11 | 2019-05-01 | 2026-01-13 |
| Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma Fevipiprant 150 mg, Fevipiprant 450 mg, Placebo - Nasal Polyps | Phase 3 | Completed | Novartis Pharmaceuticals | 98 | 2019-03-26 | 2021-10-11 |
| Systemic Corticosteroids Avoidance Study in Severe Asthma Patients Placebo once daily, QAW039 150 mg once daily, QAW039 450 mg once daily - Asthma | Phase 3 | Terminated | Novartis Pharmaceuticals | 604 | 2018-12-13 | 2021-10-11 |
| Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma QAW039, Placebo - Asthma | Phase 3 | Completed | Novartis Pharmaceuticals | 675 | 2017-11-01 | 2026-01-13 |
| Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma QAW039, Placebo - Asthma | Phase 3 | Completed | Novartis Pharmaceuticals | 704 | 2017-10-31 | 2026-01-13 |
| Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects QAW039, QAW39A, QAW39A2107 - Renal Insufficiency | Phase 1 | Completed | Novartis Pharmaceuticals | 45 | 2017-07-05 | 2020-12-11 |
| Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects Fevipiprant - Hepatic Impairment | Phase 1 | Completed | Novartis Pharmaceuticals | 42 | 2017-05-31 | 2020-12-11 |
| Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment QAW039 150 mg, QAW039 450 mg, Placebo - Asthma | Phase 3 | Terminated | Novartis Pharmaceuticals | 2538 | 2017-03-21 | 2020-10-12 |
| Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. QAW039, Placebo - Asthma | Phase 3 | Completed | Novartis Pharmaceuticals | 894 | 2015-12-11 | 2026-10-07 |
| Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. QAW039, Placebo - Asthma | Phase 3 | Completed | Novartis Pharmaceuticals | 877 | 2015-12-03 | 2021-05-03 |
| Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis. QAW039, Placebo - Atopic Dermatitis | Phase 2 | Completed | Novartis Pharmaceuticals | 103 | 2013-06-01 | 2015-12-15 |
| A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients QAW039, Placebo QAW039, Fluticasone 250 mcg - Asthma | Phase 2 | Completed | Novartis Pharmaceuticals | 345 | 2013-05-01 | 2017-03-20 |
| A Clinical Trial to Test How Well Two Drugs, QAW039 and Montelukast Work Both Individually and Together, to Target Allergic Rhinitis Using an Environmental Exposure Chamber QAW039, Montelukast, Placebo - Allergic Rhinitis | Phase 2 | Completed | Novartis Pharmaceuticals | 188 | 2012-10-01 | 2016-11-18 |
| Safety and Efficacy of QAW039 in Sputum Eosinophilia and Persistent Asthma QAW039, Placebo - Asthma | Phase 2 | Completed | Novartis Pharmaceuticals | 61 | 2012-02-01 | 2013-10-09 |
| Dose Finding Study for QAW039 in Asthma QAW039, Montelukast, Placebo - Asthma | Phase 2 | Completed | Novartis Pharmaceuticals | 1043 | 2011-08-01 | 2020-12-19 |
| Efficacy, Safety, and Pharmacokinetics of QAW039 QAW039 capsules once daily for 28 days, Placebo to QAW039 capsules once daily for 28 days, Fluticasone propionate inhaler twice daily for 28 days - Persistent Asthma | Phase 2 | Completed | Novartis Pharmaceuticals | 170 | 2010-11-01 | 2020-12-19 |
Asthma (13) · Bronchial Diseases (2) · Dyspnea (2) · Eosinophilia (2) · Lung Diseases (2) · Respiratory Hypersensitivity (2) · Dermatitis, Atopic (1) · Hypersensitivity (1) · Immune System Diseases (1) · Lung Diseases, Obstructive (1) · Nasal Polyps (1) · Nose Diseases (1) · Pulmonary Disease, Chronic Obstructive (1) · Renal Insufficiency (1) · Respiratory Tract Diseases (1)
United States (13) · Germany (12) · Argentina (7) · Belgium (7) · Hungary (6) · Romania (6) · South Africa (6) · United Kingdom (6) · Bulgaria (5) · Canada (5) · Colombia (5) · Czechia (5) · Greece (5) · India (5) · Netherlands (5)
Richard Kay (1)
PMID 32979986, PMID 27354118, PMID 27503237, PMID 28838980, PMID 34895218
2018 (3), 2015 (2), 2016 (2), 2017 (2)